» Articles » PMID: 12368209

Caveolin-1 Mutations (P132L and Null) and the Pathogenesis of Breast Cancer: Caveolin-1 (P132L) Behaves in a Dominant-negative Manner and Caveolin-1 (-/-) Null Mice Show Mammary Epithelial Cell Hyperplasia

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2002 Oct 9
PMID 12368209
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Caveolin-1 (Cav-1) is the principal structural protein of caveolae membranes that are found in most cells types, including mammary epithelial cells. Recently, we mapped the human CAV1 gene to a suspected tumor suppressor locus (7q31.1/D7S522) that is deleted in a variety of human cancers, as well as mammary tumors. In addition, the CAV1 gene is mutated (P132L) in up to approximately 16% of human breast cancers. The mechanism by which deletion or mutation of the Cav-1 gene contributes to mammary tumorigenesis remains unknown. To understand the role of the Cav-1 (P132L) mutation in the pathogenesis of human breast cancers, we generated the same mutation in wild-type (WT) Cav-1 and studied its behavior in cultured cells. Interestingly, the P132L mutation leads to formation of misfolded Cav-1 oligomers that are retained within the Golgi complex and are not targeted to caveolae or the plasma membrane. To examine whether the Cav-1 (P132L) mutant behaves in a dominant-negative manner, we next co-transfected cells with Cav-1 (P132L) and WT Cav-1, and evaluated their caveolar targeting. Our results indicate that Cav-1 (P132L) behaves in a dominant-negative manner, causing the mislocalization and intracellular retention of WT Cav-1. Virtually identical results were obtained when Cav-1 (P132L) was stably expressed at physiological levels in a nontransformed human mammary epithelial cell line (hTERT-HME1). These data provide a molecular explanation for why only a single mutated CAV1 allele is found in patients with breast cancer. Thus, we next investigated if functional inactivation of Cav-1 gene expression leads to mammary tumorigenesis in vivo. For this purpose, we performed mammary gland analysis on Cav-1-deficient mice (-/-) that harbor a targeted disruption of the Cav-1 gene (a null mutation). Interestingly, we show that inactivation of Cav-1 gene expression leads to mammary epithelial cell hyperplasia, even in 6-week-old virgin female mice. These data clearly implicate loss of functional Cav-1 in the pathogenesis of mammary epithelial cell hyperplasia, and suggest that Cav-1-null mice represent a novel animal model to study premalignant mammary disease.

Citing Articles

Caveolae with GLP-1 and NMDA Receptors as Crossfire Points for the Innovative Treatment of Cognitive Dysfunction Associated with Neurodegenerative Diseases.

Nakashima M, Suga N, Yoshikawa S, Matsuda S Molecules. 2024; 29(16).

PMID: 39203005 PMC: 11357136. DOI: 10.3390/molecules29163922.


Caveolin and NOS in the Development of Muscular Dystrophy.

Nakashima M, Suga N, Yoshikawa S, Matsuda S Int J Mol Sci. 2024; 25(16).

PMID: 39201459 PMC: 11354531. DOI: 10.3390/ijms25168771.


Early proteostasis of caveolins synchronizes trafficking, degradation, and oligomerization to prevent toxic aggregation.

Morales-Paytuvi F, Fajardo A, Ruiz-Mirapeix C, Rae J, Tebar F, Bosch M J Cell Biol. 2023; 222(9).

PMID: 37526691 PMC: 10394380. DOI: 10.1083/jcb.202204020.


The building blocks of caveolae revealed: caveolins finally take center stage.

Kenworthy A Biochem Soc Trans. 2023; 51(2):855-869.

PMID: 37082988 PMC: 10212548. DOI: 10.1042/BST20221298.


A deep learning-based tool for the automated detection and analysis of caveolae in transmission electron microscopy images.

Aboy-Pardal M, Jimenez-Carretero D, Terres-Dominguez S, Pavon D, Sotodosos-Alonso L, Jimenez-Jimenez V Comput Struct Biotechnol J. 2022; 21:224-237.

PMID: 36544477 PMC: 9755247. DOI: 10.1016/j.csbj.2022.11.062.


References
1.
Fra A, Mastroianni N, Mancini M, Pasqualetto E, Sitia R . Human caveolin-1 and caveolin-2 are closely linked genes colocalized with WI-5336 in a region of 7q31 frequently deleted in tumors. Genomics. 1999; 56(3):355-6. DOI: 10.1006/geno.1998.5723. View

2.
Volonte D, Galbiati F, Lisanti M . Visualization of caveolin-1, a caveolar marker protein, in living cells using green fluorescent protein (GFP) chimeras. The subcellular distribution of caveolin-1 is modulated by cell-cell contact. FEBS Lett. 1999; 445(2-3):431-9. DOI: 10.1016/s0014-5793(99)00164-7. View

3.
Engelman J, Zhang X, Lisanti M . Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5' promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett. 1999; 448(2-3):221-30. DOI: 10.1016/s0014-5793(99)00365-8. View

4.
Pflug B, Reiter R, Nelson J . Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate. 1999; 40(4):269-73. DOI: 10.1002/(sici)1097-0045(19990901)40:4<269::aid-pros9>3.0.co;2-6. View

5.
Schlegel A, Schwab R, Scherer P, Lisanti M . A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1. The caveolin scaffolding domain is both necessary and sufficient for membrane binding in vitro. J Biol Chem. 1999; 274(32):22660-7. DOI: 10.1074/jbc.274.32.22660. View